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Paramyosin and Sm14 are two of the six antigens selected by the World Health Organization as candidates to
compose a subunit vaccine against schistosomiasis. Both antigens are recognized by individuals naturally resistant
to Schistosoma mansoni infection and induced protective immunity in the murine model. Three Sm14 epitopes and
eleven paramyosin epitopes were selected by their ability to bind to different HLA-DR molecules using the TEPITOPE
computer program, and these peptides were synthetically produced. The cellular recognition of Sm14 and paramyosin
epitopes by peripheral blood mononuclear cells of individuals living in endemic area for schistosomiasis was tested
by T cell proliferation assay. Among all Sm14 and paramyosin epitopes studied, Sm14-3 was preferentially recog-
nized by individuals naturally resistant to S. mansoni infection while Para-5 was preferentially recognized by
individuals resistant to reinfection. These two peptides represent promising antigens to be used in an experimental
vaccine against schistosomiasis, since their preferential recognition by resistant individuals suggest their involve-
ment in the induction of protective immunity.
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Schistosomiasis is an important parasitic disease,
which affects more than 200 million people in 74 countries
around the world and causes approximately 20,000 death
per year (Bergquist 2002). Currently, schistosomiasis con-
trol strategy is mainly based on the treatment of infected
individuals by chemotherapy with safe and effective drugs
(Harder 2002). In spite of two decades of chemotherapy,
the number of infected people remains almost the same
(Bergquist 1998). Therefore, vaccination as a way to con-
trol schistosomiasis would contribute enormously to dis-
ease eradication, mainly because immunization provides
long-lasting immunity to the disease.
Among schistosome proteins tested as immunogens
in experimental immunization protocols, Sm14 and
paramyosin are two promising molecules to compose a
subunit vaccine against schistosomiasis (Bergquist 1995).
Paramyosin or Sm97 is a myofibrillar protein of 97 kDa
located in the muscles and tegument of schistosome worms
(Pearce et al. 1988). Both cellular and humoral immune
responses are important mechanisms in the protective
immunity induced by paramyosin immunization. Passive
transfer of monoclonal antibody against paramyosin to
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naive mice, in an early stage of the challenge infection,
results in partial but significant reduction in worm burden
(Lanar et al. 1986). Also, immunization with recombinant
or purified paramyosin induces significant level of pro-
tection, which involves interferon-γ (IFN-γ) production
by stimulated T cells (Pearce et al. 1988). Studies of the
human immune response to paramyosin support the po-
tential use of this protein as a vaccine candidate, since S.
mansoni paramyosin is strongly recognized by sera of
individuals naturally resistant to parasite infection
(Correa-Oliveira et al. 1989) and induces the production of
high levels of IFN-γ by peripheral blood mononuclear cells
(PBMCs) of these individuals (Ribeiro de Jesus et al. 2000).
Regarding Sm14, it is a 14 kDa S. mansoni fatty acid-
binding protein involved in fatty acid trafficking (Moser
et al. 1991). Immunization of mice with rSm14 induces par-
tial protection that is increased by the use of the recombi-
nant form of interleukin (IL-12) as adjuvant. Both immuni-
zation protocols induce a Th1 cytokine profile with high
IFN-γ production and low IL-4. The protective immunity
induced by rSm14/rIL-12 immunization is dependent on
endogenous IFN-γ and tumor necrosis factor-α (TNF-α),
since mice deficient on IFN-γ and TNFR p55 genes are
not able to mount a protective response when submitted
to this vaccination protocol (Fonseca et al. 2004). Fur-
thermore, another study performed by our group demon-
strated that CD4+ T cells from naturally resistant indi-
viduals living in an endemic area of schistosomiasis,
mounted a Th1-type of immune response to rSm14 based
on IFN-γ and TNF-α production (Brito et al. 2000a).  More-
over, T cell proliferative responses from these individuals
to rSm14 are totally abrogated when these cells were treated
with anti-IFN-γ antibodies.  This result demonstrates that
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T cell activation to rSm14 in these individuals, who are
the model for natural resistance to human schistosomia-
sis, is dependent on IFN-γ suggesting a role for human
Th1 pattern of immune response in the control of this
parasitic disease.
Modern vaccines should contain epitopes able to in-
duce protective response in the majority of the popula-
tion, therefore it turns relevant to study which schisto-
some antigen epitopes are recognized by human T cells.
Here, we report the cellular recognition by PBMCs of in-
dividuals living in endemic area for schistosomiasis in
response to Sm14 and paramyosin synthetic peptides se-
lected using the TEPITOPE algorithm, that can predict
peptide binding to multiple HLA-DR molecules.
MATERIALS AND METHODS
Patients - Heparinized peripheral blood was obtained
from individuals living in an endemic area for schistoso-
miasis; these individuals were classified in four groups
regarding their infection status. These groups were, in-
fected (INF), resistant to reinfection (RR), susceptible to
reinfection  (SR), and naturally resistant (NR) individuals.
Details regarding sex, age, classification parameters are
described in the Table.  These patients or their legal guard-
ians gave informed consent after explanation of the pro-
tocol that had been previously approved by the Ethical
Committee of the Federal University of Minas Gerais.
Antigen preparation - SWAP (soluble adult worm an-
tigen preparation) was prepared as previously described
(Colley et  al. 1977). Recombinant Sm14 was produced
using the pMal-c2 expression system as previously de-
scribed (Brito et al. 2000b). Protein concentration was
determined according to Bradford’s method (1976).
Synthetic peptides -  17 or 18-mer synthetic peptides
containing epitopes of Sm14 and paramyosin selected
using the TEPITOPE algorithm computer program, were
purchased from  Mimotope (San Diego, CA, US). All 17-
18 mer peptides were synthetically produced by solid-
phase method and were purified by high-performance liq-
uid chromatography.
T cell proliferation assay - PBMC were isolated from
peripheral blood by Ficoll-Hypaque density gradient cen-
trifugation (d = 1.077), washed three times with sterile
saline, and incubated in RPMI 1640 medium (Gibco)
supplemented with 10% of normal human AB serum (Sigma,
St. Louis, MO), 100 U/ml of penicillin G sodium, 100 mg/ml
of streptomycin sulfate, 250 ng/ml of amphatericin B. In
proliferation assay, cells cultures from PBMC from stud-
ied individuals were carried out in triplicate in 96-well-flat-
bottom culture plates (105 cells/well; final volume 0.2 ml)
with recombinant Sm14 (50 µg/ml), SWAP (25 µg/ml), Sm14
peptides (50 µM) and paramyosin peptides (10 µM).
Phytohaemaglutinin  (PHA) (2 µg/ml) was used as posi-
tive control and unstimulated culture was used as nega-
tive control. Plates were incubated in 5% CO2 at 37
oC for
five days and cultures were pulsed with 0.5 µCi/well [3H]-
thymidine (Amersham Bioscience, Sydney, Australia) for
18 h. [3H]-thymidine incorporation was measured using a
Beta Counter apparatus (Packard, IL). Data are represented
as proliferation index (PI) defined as mean cpm experi-
mental triplicates with antigen/mean cpm of triplicates of
culture medium control.  PI values ≥ 2.0 were considered
positive.
Statistic analysis - Mann-Whitney’s rank sum test
was used to compare continuous variables in T cell prolif-
eration assays.
RESULTS
T cell epitope prediction - Fig. 1 shows the result of
TEPITOPE analysis of the amino acid sequence of Sm14
and paramyosin at 3% threshold. Promiscuous Sm14
epitopes are observed in the N-terminal region of the pro-
tein while paramyosin promiscuous epitopes are distrib-
uted throughout the entire amino acid sequence of this
antigen (data not shown). Three Sm14 epitopes were se-
lected by their ability to bind with high affinity to several
HLA-DR molecules used in TEPITOPE analysis: Sm14-1
(1-18) MSSFLGKWKLSESHNFDA; Sm14-2 (32-48)
IGNTVTPTVTFTMDGDK and Sm14-3 (53-69) TES
TFKNISCTFKFGEE.  Sm14-1 was the most promiscuous
epitope able to bind to 10/25 HLA-DR molecules followed
by Sm14-3 and Sm14-2 (Fig. 1). Eleven paramyosin epitopes
were selected by TEPITOPE analysis: Para-1 (6-20)
TESHVKISRTIYRGVSP; Para-2 (13-29) SRTIYR
GVSPSTTRLES; Para-3 (151-167) LDGALKAKQSA
ESKLEG; Para-4 (168-184) LDSQLNRLKSLTDDLQR; Para-
TABLE
Study population
Age Sex
Group Infection status Description (mean ± SD) (male/female)
Natural resistant Not infected Individuals living in an endemic area for schistosomiasis that 52,63 ± 9,96 5/6
(NR) n =11 although water contact, present stool negative examination
Resistant to Not infected Individuals living in an endemic area for schistosomiasis that    26,8 ± 25,5 2/6
reinfection although water contact, present stool negative examination
(RR) n = 8 after praziquantel treatment
Susceptible to Schistosoma Individuals living in an endemic area for schistosomiasis that     22,9 ± 17,7 5/8
reinfection mansoni present stool positive examination after praziquantel
(SR) n = 13 treatment
Infected S. mansoni Individuals living in an endemic area for schistosomiasis with   27,61 ± 17,46 6/10
(INF) n = 16 stool positive examination
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5 (210-226) YEAQILNYSKAKSSLES; Para-6 (355-371)
NSELIRRAKAAESLASD; Para-7 (399-415) RLKSLVNDLT
DKNNLLE; Para-8 (584-600) AENNLQITEHKRLQLAN;
Para-9 (676-692) NNEVLRLADELRQEQGN; Para-10 (760-
776) FERQYKELQTQAEDDRR; Para-11 (830-846)
AERTVTVRRVGPGGRAV. Among paramyosin epitopes,
Para-6 is the most promiscuous epitope able to bind 6/25
HLA-DR molecules according to TEPITOPE analysis, fol-
lowed by Para-5, Para-1, Para-4, Para-9, Para-2, Para-7, Para-
11, Para-3, Para-8 and Para-10 (Fig. 1).
Proliferative responses to synthetic peptides. The
purified synthetic peptides were used as antigens in cell
proliferation assays using PBMCs of individuals living in
endemic area for schistosomiasis to test human T cell rec-
ognition of Sm14 and paramyosin epitopes. In order to
select peptides that could be recognized by resistant ver-
sus susceptible individuals, we compared the prolifera-
tion index of the NR group versus INF individuals, and
RR patients versus the SR group.  Among Sm14 peptides,
Sm14-3 is the epitope preferentially recognized by PBMCs
of individuals naturally resistant to S. mansoni infection
compared to infected patients (Fig. 2A).  Recombinant
Sm14 is also recognized by PBMCs of NR individuals.
Paramyosin synthetic peptides are recognized by a higher
number of individuals living in endemic area for schisto-
somiasis (Fig. 2C, D). However, Para-5 is preferentially
recognized by PBMCs of individuals resistant to S.
mansoni reinfection (Fig. 2D), while Para-11 is preferen-
tially recognized by PBMCs of infected individuals (Fig.
2C).
DISCUSSION
The development of  vaccines for complex parasites,
such as S. mansoni, is a great challenge. Given the persis-
tent lack of an effective immunogen, several vaccine de-
velopment strategies have been tried, such as the use of
synthetic peptides.  The amino acid sequence of most
schistosome vaccine antigens shows several identical
residues with the mammalian counterpart.  Immunization
with the whole parasite protein or conserved regions of
the molecule may potentially induce autoimmune re-
sponses.  Therefore, it is important to select the least
conserved peptides of schistosome antigens, such as
Sm14 and paramyosin, to be used in a vaccine formula-
tion.  In a recent study performed in an endemic area for
schistosomiasis in Egypt, cellular immune response to
Sm14 and paramyosin was related with resistance to rein-
fection (Al-Sherbiny et al. 2003). These findings reinforce
the importance of identifying T cell epitopes on these
antigens that may be involved in the induction of protec-
tive immunity.
Fig. 1: number of HLA class II molecules that binds to Sm14 and
paramyosin peptides at 3% threshold.
Fig. 2: proliferative responses to recombinant Sm14 and Sm14 peptides (A and B) or paramyosin peptides (C and D) of peripheral blood
mononuclear cells from individuals naturally resistant to Schistosoma mansoni infection (NR), infected individuals (INF), individuals
resistant to reinfection (RR), and susceptible to reinfection (SR). Bars represent the mean of proliferation index (cpm of stimulated
cultures/cpm of unstimulated cultures) ± standard deviation (SD). Statistically significant differences (P < 0.05) between NR vs INF group
are denoted by an asterisk and  between RR vs SR group by two asterisks.
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Herein, we used the TEPITOPE computer program that
is a matrix-based algorithm that predicts binding to 25
distinct HLA-DR molecules.  This program allows poten-
tial selection of high affinity-binding peptides in Sm14
and paramyosin, those with the highest chance of elicit-
ing an effective T cell response. Exogenous peptides bear-
ing T-cells epitopes prime the immune system probably
by binding to empty MHC molecules present on the sur-
face of antigen-presenting cells.  However, a single epitope
defined in a host of a particular MHC type may therefore
be an inadequate substitute for intact antigen in an out-
bred  population that means that multiple and different T-
cell epitopes are needed for an effective vaccine.  The
majority of the studies defining T-cell epitopes in schisto-
some protective antigens have used the animal model to
screen these synthetic peptides.  Here, we have tested
peptides using human T-cells from resistant and suscep-
tible individuals living in an endemic area for schistoso-
miasis.
Synthetic peptides as vaccine candidates have sev-
eral advantages, they are easy to produce and high quan-
tities of a homogeneous product may be obtained while
avoiding complicated purification procedures of recom-
binant protein vaccines. Another advantage is that T-cell
and B-cell epitopes may be selected.  Lately, immuodomi-
nants epitopes of others S. mansoni antigens have also
been identified and successfully used as antigens in im-
munization protocols. A B-cell epitope of 9B antigen, pep-
tides from SG3PDH or from Sm-37-GAPDH together with
Sm-10-DLC were able to induce partial protective immu-
nity in the murine model (Tarrab-Hazdai et al. 1998, Argiro
et al. 2000, Tallima et al. 2003). Regarding Sm14 and
paramyosin, only B-cell epitopes, different from the pep-
tides described in this study, have been previously iden-
tified (Nara et al. 1997, Vilar et al. 2003).
In conclusion, our study identified two peptides, Sm14-
3 and Para-5, as promising epitopes to compose an anti-
schistosomiasis vaccine. These peptides are preferentially
recognized by PBMCs of resistant individuals and might
be involved in the induction of antigen-specific resistance
to human schistosomiasis. Our long term research goal is
to assemble multivalent constructs containing schisto-
some B- and T-cell epitopes recognized by resistant indi-
viduals living in an endemic area for schistosomiasis and
test them for protective immunity in mice.  In this ap-
proach, synthetic genes coding for amino acid sequence
of epitopes from various antigens are going to be inserted
into a DNA vaccine vector for mammalian expression.
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